GCP
CGTX icon

GSA Capital Partners’s Cognition Therapeutics CGTX Stock Holding History

GSA Capital Partners’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,843
Closed -$16K – 1772
2025
Q4 		$16K Sell
11,843
-184,514
-94% -$299K ﹤0.01% 1604
2025
Q3 		$265K Buy
+196,357
New +$268K 0.02% 1270
2025
Q2 		– Sell
-22,354
Closed -$9K – 1774
2025
Q1 		$9K Buy
+22,354
New +$13.1K ﹤0.01% 1592

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

GSA Capital Partners's CGTX Position: Q1 2026 in Review

GSA Capital Partners sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 11,843 shares — an estimated $16K sold.

GSA Capital Partners first reported a position in CGTX in Q1 2025 and held it in 3 quarters. The position peaked at $265K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • GSA Capital Partners reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 11,843 Cognition Therapeutics shares in Q1 2026, an estimated $16K.
  • GSA Capital Partners first reported a position in Cognition Therapeutics in Q1 2025 and held it in 3 quarters.
  • GSA Capital Partners's Cognition Therapeutics position peaked at $265K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.